Atorvastatin indications and usage: Difference between revisions
Jump to navigation
Jump to search
(Created page with " LIPITOR is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to: * Reduce the risk of MI, stroke, revascularization procedures, and angina ...") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Abciximab}} | |||
{{CMG}}; {{AE}} {{PB}} | |||
==Indications and Usage== | |||
LIPITOR is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to: | LIPITOR is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to: | ||
Revision as of 21:54, 29 January 2014
Template:Abciximab Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Indications and Usage
LIPITOR is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to:
- Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors.
- Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors.
- Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD.
- Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia.
- Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia.
- Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH).
- Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy .
Limitations of Use
LIPITOR has not been studied in Fredrickson Types I and V dyslipidemias.